AnaptysBio (ANAB) has disclosed a new risk, in the Regulation category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AnaptysBio faces a significant business risk as outlined in the risk factor titled ‘3333Item’. This risk could potentially impact their operational efficiency and financial stability. External analysts suggest that the company may need to implement strategic measures to mitigate this risk effectively. Failure to address this issue could result in adverse effects on their market position and investor confidence.
The average ANAB stock price target is $54.50, implying 122.00% upside potential.
To learn more about AnaptysBio’s risk factors, click here.